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Dr Michael A. Acker (Philadelphia, Pa). Ranjit, great
presentation and very important data that you have presented
with your colleagues.
I think that for the first time that we know that it’s not a free
lunch, doing simultaneous valvular procedures while putting in
an LVAD. The bar to add additional valve procedures, especially
AV procedures has gotten less and less and now we know there
is a cost.
First question, I have 4, we know that INTERMACS class
consistently predicts short, intermediate, and long-term survival.
Did you look at that? And if not, why not? That was probably
available.
Second question, clearly the addition of an aortic valve
procedure, whatever procedure you do, results in increased
mortality, probably due to a mandatory ischemic time and, in
your article, which you didn’t show today, a significant increase
in bypass times. Given that, and a 2-year survival that, frankly,
is worse than the 2-year survival for INTERMACS 1, would you
recommend that unless there is moderate AI or greater not to touch
the aortic valve?
Third question, what’s your hypothesis for the poor 2-year
survival in the aortic valve group?
And finally, switching gears to the tricuspid valve, it’s a shame
you don’t have echo data, because there is still a controversy what
to dowithmoderate TR, and obviously it’s a marker for worse right
heart function. But is there any way to go back and actually
compare patients who had moderate TR who had a ring versusThe Journal of Thoracic and Cathose patients who did not have a ring and to see what their
long-term survival was?
Dr John. Thank you, Michael. I’ll start with your last question
first. Because of the lack of baseline data, it’s going to be hard to
compare who got a tricuspid valve or not. So the only message
I could take from this is it will be interesting to speculate about
the mortality and postoperative RV dysfunction of those patients
with significant valvular pathologies, such as moderate or severe
TR, who did not get a procedure.
I can tell you from our own personal experience that I’ve drifted
toward being more aggressive in fixing moderate to severe TR in
these patients compared with earlier in our experience.
We certainly didn’t have INTERMACS data for this study, but
that’s something we can go back and look at. However, I think
there is a slew of other important preoperative variables that do
reflect the higher risk in the patients getting a valvular procedure.
In the aortic valve procedures, certainly these patients were older
and the higher mortality is disturbing. I would also like to say that 3
or 4 studies have shown that the only reason why we fix an aortic
valve at the time of VAD implant is mild to moderate AI. It’s
certainly not harming the patient right now, but the worry is that
is it going to affect the patient in 1, 2, or 3 years down the road.
And as someone once told me, before we think of 3-, 5-, 10-year
survival, get the patient home first. So maybe we are being a little
too aggressive in fixing mild to moderate AI, and I think our goal
should be to identify risk factors to find out exactly which patients
develop severe AI and is that a mortality problem in these patients
after prolonged periods of time?
Dr Acker. What’s your hypothesis of why the survival is
dramatically different, not early on, but after that first period,
why are they dying at a faster rate than if they don’t have an aortic
valve procedure?
Dr John. The only thing I can think of is closure of the aortic
valve; is there a higher risk because of no flow in the LVOT, a
higher risk of thrombus developing around the aortic valve and
that leading to thromboembolic complications? However, I should
also state that there was no real reasons in terms of the adverse
events and mortality in terms of causes of death that could explain
the difference. So that still is a puzzle that needs to be sorted out.rdiovascular Surgery c Volume 147, Number 2 589
